The goal of this trial is to learn how the Nerivio® device works to treat Amplified Musculoskeletal Pain Syndrome (AMPS) in children ages 8-18. Nerivio® is a wearable device that activates specific nerves in the upper arm. This causes a response from the brain that has been helpful for people who experience migrane headaches. The main questions this study aims to answer are:

• How well does the Nerivio® device help in reducing pain in children with AMPS?
• Does the use of the Nerivio® device help improve quality of life in children with AMPS?
• How satisfied are children and their families with the use of the Nerivio® device for treatment of AMPS?

Researchers will compare the use of the Nerivio® device with usual treatment for AMPS (including pain medications, physical therapy, and other interventions) to see how well the Nerivio® device helps control pain.

Participants will be in one of two groups, decided by:

• Those who are in the "control" group will use their usual practices to control pain.
• Those who are in the "intervention" group will use the Nerivio® device once every other day.

All participants in the "control group" will:

• Complete surveys and answer questions about their pain and how it affects their daily life
• Use their existing methods for pain control.

All participants in the "intervention" group will:

• Complete surveys and answer questions about their pain and how it affects their daily life
• Learn how to work the Nerivio® device and smartphone app.
• Use the Nerivio® device every other day (every 48 hours).

Inclusion Criteria:

• Confirmed diagnosis of AMPS by a medical provider experienced in pediatric pain management
• Chronic musculoskeletal pain ≥3 months
• Baseline pain intensity of ≥4 on a 0-10/10 Numeric Rating Scale (NRS)
• Able to comprehend and follow instructions for the device use
• Access to compatible smartphone or device to operate the Nerivio app
• Commit to a four-week treatment and data collection period
• Must be age 8 years - 18 years old

Exclusion Criteria:

• Active autoimmune disease.
• Use of implantable electronic medical devices.
• Neurological disorders that impair study participation as determined by the enrolling provider.
• Severe Mood disorders
• Recent change in pain medications or psychotropic medications (within last 4 weeks)
• Currently or plan to be pregnant (Urine or blood HCG testing done upon enrollment)
• Inability to comply with study procedures or use the device as directed